Matinas Biopharma Holdings Inc (MTNB) Stock: A Closer Look at the Market Potential
Company’s 36-month beta value is 1.53.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as
Company’s 36-month beta value is 1.53.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 0 as
Matinas Biopharma Holdings Inc (AMEX: MTNB)’s stock price has increased by 12.21 compared to its previous closing price of 0.27. However, the company has seen
Matinas Biopharma Holdings Inc (AMEX: MTNB)’s stock price has soared by 26.00 in relation to previous closing price of 0.24. Nevertheless, the company has seen
Matinas Biopharma Holdings Inc (AMEX: MTNB) has experienced a decline in its stock price by -7.88 compared to its previous closing price of 0.25. However,
The stock of Matinas Biopharma Holdings Inc (MTNB) has gone up by 14.35% for the week, with a 38.64% rise in the past month and
In the past week, MTNB stock has gone up by 22.75%, with a monthly gain of 30.15% and a quarterly surge of 12.12%. The volatility
© 2024, Fueled by Smart TechOne
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.